Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Leukemia
Hlavní autoři: Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan T., Jakubowiak, Andrzej, Dingli, David, Cornell, Robert F., Hofmeister, Craig C., Siegel, David, Berdeja, Jesus G., Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol Ann, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay K., Richter, Joshua, Abonour, Rafat, Parker, Terri L., Yee, Andrew J., Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja C., Mohty, Mohamad, Choquet, Sylvain, Unger, T. J., Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Dimopoulos, Meletios Athanasios
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449872/
https://ncbi.nlm.nih.gov/pubmed/32094461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0756-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky